- Active not recruitingPHASE3
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
This study looks at new drug combinations for advanced bladder cancer that hasn't been treated before. It compares them to standard chemotherapy to see if they're safer and work better.
For: Urothelial CancerUnited States · Australia · Austria - Active not recruitingPHASE2
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
This study is testing a new drug, tremelimumab, against a dummy treatment (placebo) for people with a type of cancer called malignant mesothelioma that cannot be removed by surgery. It aims to see if the new drug can help patients.
For: Unresectable Pleural or Peritoneal Malignant MesotheliomaUnited States · Australia · Belgium - Active not recruitingPHASE3
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
This study, called POSEIDON, is testing new drug combinations for people with a type of lung cancer called non-small cell lung cancer (NSCLC). It's comparing usual chemotherapy with combinations of two new drugs, durvalumab and tremelimumab, to see if they work better.
For: Non Small Cell Lung Cancer NSCLCUnited States · Brazil · Bulgaria - Active not recruitingPHASE3
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
This study looks at new drug combinations for bladder cancer that has spread into the muscle. It compares them to standard treatment for people who can't take or don't want cisplatin chemotherapy before surgery to remove their bladder. The aim is to find more effective and safe options.
For: Muscle Invasive Bladder CancerUnited States · Argentina · Austria - Active not recruitingPHASE3
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
This study looks at new treatments (Durvalumab, Tremelimumab) for a type of lung cancer, Small Cell Lung Cancer, after initial strong treatment. It aims to see if these drugs can stop the cancer from coming back.
For: Small Cell Lung CancerUnited States · Argentina · Belgium - Active not recruitingPHASE2
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
This study is looking at new drug combinations for metastatic lung cancer. It combines durvalumab and tremelimumab, which are treatments that help your body's immune system fight cancer, sometimes with standard chemotherapy. We want to see if these new combinations are more effective.
For: Lung Cancer MetastaticAustralia · Canada - Active not recruiting
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
This study looks at how well different treatments work for adults with liver cancer that can't be removed by surgery. Researchers are collecting health information from medical records to find the best next steps for people who have already had a specific type of first-line therapy.
For: Unresectable Hepatocellular CarcinomaUnited States · Argentina · Brazil - RecruitingPHASE3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
This study is testing new combinations of medicines for advanced liver cancer (hepatocellular carcinoma) that can't be cured with surgery. It compares different drug blends to a common treatment to see which works best and is safest.
For: Hepatocellular CarcinomaUnited States · Australia · Brazil - RecruitingPHASE3
Renal Adjuvant MultiPle Arm Randomised Trial
This study looks at new treatments for kidney cancer (renal cell carcinoma) after surgery. It compares two drugs, durvalumab and tremelimumab, given alone or together, against standard monitoring. The aim is to see if these drugs can stop the cancer from coming back or help people live longer.
For: Renal Cell CarcinomaUnited Kingdom - Active not recruitingPHASE2
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
This study looks at new drug combinations (Durvalumab and Tremelimumab with FOLFIRI chemotherapy) for advanced stomach or food pipe cancer that has already been treated. It aims to see how well patients respond and if these combinations can help people live longer.
For: Gastric Adenocarcinoma · Gastric CancerFrance - RecruitingPHASE2, PHASE3
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
This study is looking into new treatments for advanced liver cancer (hepatocellular carcinoma). It compares new drug combinations, livmoniplimab with budigalimab, against existing treatments to find the best dose and see how well they work and what side effects they might have.
For: Hepatocellular CarcinomaUnited States · France · Italy - Active not recruitingPHASE2
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
This study looks at new ways to treat a type of throat cancer called oropharyngeal squamous cell carcinoma, linked to HPV. It compares standard radiotherapy and chemotherapy with newer immunotherapy drugs, durvalumab and tremelimumab, to see if they can work better at stopping the cancer from coming back.
For: Oropharyngeal Squamous Cell CarcinomaBelgium · Canada · Italy - RecruitingPHASE2
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
This study looks at combining special medicines called immunotherapy with propranolol, and sometimes chemotherapy, for advanced pancreatic, liver, or bile duct cancers. It aims to see how safe and effective this new treatment approach is for patients.
For: Pancreatic Cancer · Hepatocellular Cancer · Biliary Tract CancerCanada - Active not recruitingPHASE1
Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
This study is looking for the right dose of new cancer medicines, durvalumab and tremelimumab, given with or without standard chemotherapy, for advanced solid cancers. It aims to find a dose that helps treat cancer without causing very severe side effects.
For: Solid MalignanciesCanada - RecruitingPHASE2
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
This study is looking at a new way to treat a type of liver cancer that can't be removed with surgery. It combines two immunotherapy drugs, durvalumab and tremelimumab, with a radiation treatment called Y-90 SIRT. The aim is to see if this combination is safe and effective.
For: Hepatocellular Carcinoma Non-resectable · HCCGermany - Active not recruitingPHASE3
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
This study looks at two drugs, durvalumab and tremelimumab, as a first treatment for advanced liver cancer that can't be removed by surgery. Researchers want to see how safe and effective this combination is.
For: Advanced Hepatocellular CarcinomaUnited States · France · Germany